^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    LucenceINSIGHT™

    Company:
    Lucence
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    7ms
    Initial experience in a real-world Asian cohort with a circulating tumor DNA (ctDNA) mutation-based multi-cancer early detection (MCED) assay (ESMO Asia 2023)
    A majority of cases detected were not covered under traditional screening guidelines. These findings provide additional support for the use of ultrasensitive mutation-based assays for screening.
    Real-world evidence • Clinical • Circulating tumor DNA • Real-world
    |
    LucenceINSIGHT™
    12ms
    Lucence launches LucenceINSIGHT to detect cancer earlier (Lucence Press Release)
    "Lucence unveiled LucenceINSIGHT™, its pioneering multi-cancer early detection (MCED) blood test, at their US headquarters...Lucence is launching LucenceINSIGHT™, an MCED test first internationally and with a follow-up U.S. launch in Q3 2023. This ctDNA-based liquid biopsy test screens for 10 common cancers in one blood draw."
    Launch
    |
    LucenceINSIGHT™